Xin Zhong Chang



  1. Wang L, Hu X, Wang P, Shao Z. Integrative 3' Untranslated Region-Based Model to Identify Patients with Low Risk of Axillary Lymph Node Metastasis in Operable Triple-Negative Breast Cancer. Oncologist. 2019;24:22-30 pubmed publisher
    ..This is the first 3'UTR-based model that will help identify TNBC patients with low risk of nodal involvement who are most likely to benefit from exemption axillary surgery. ..
  2. Liu Y, Jiang Y, Xu X, Hu X, Yu K, Shao Z. Comprehensive Transcriptome Profiling Reveals Multigene Signatures in Triple-Negative Breast Cancer. Clin Cancer Res. 2016;22:1653-62 pubmed publisher
    ..The multigene signature we developed can accurately predict clinical outcome and benefit of taxane chemotherapy in TNBC patients. ..
  3. Jiang Y, Liu Y, Xu X, Jin X, Hu X, Yu K, et al. Transcriptome Analysis of Triple-Negative Breast Cancer Reveals an Integrated mRNA-lncRNA Signature with Predictive and Prognostic Value. Cancer Res. 2016;76:2105-14 pubmed publisher
    ..Cancer Res; 76(8); 2105-14. ©2016 AACR. ..
  4. Jiang Y, Ma D, Suo C, Shi J, Xue M, Hu X, et al. Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. Cancer Cell. 2019;: pubmed publisher
    ..The comprehensive profile of TNBCs provided here will serve as a reference to further advance the understanding and precision treatment of TNBC. ..
  5. Hao S, Zhao Y, Peng J, Ren F, Yang W, Yu K, et al. Invasive micropapillary carcinoma of the breast had no difference in prognosis compared with invasive ductal carcinoma: a propensity-matched analysis. Sci Rep. 2019;9:286 pubmed publisher
    ..601-1.481) or overall survival (HR = 0.727; 95% CI, 0.358-1.478). Survival analysis demonstrated no statistically significant difference between IMPC and IDC, indicating that proactive or radical clinical therapy is unnecessary. ..
  6. Ren Y, Hao S, Jin X, Ye F, Gong Y, Jiang Y, et al. Effects of adjuvant chemotherapy in T1N0M0 triple-negative breast cancer. Breast. 2019;43:97-104 pubmed publisher
    ..Adjuvant chemotherapy improves recurrence-free survival in T1c TNBC patients but not in T1b. Anthracycline-based taxane-free regimens might be sufficient to achieve RFS benefits in T1N0M0 TNBC patients. ..
  7. Wang L, Yao L, Zheng Y, Xu Q, Liu X, Hu X, et al. Expression of autophagy-related proteins ATG5 and FIP200 predicts favorable disease-free survival in patients with breast cancer. Biochem Biophys Res Commun. 2015;458:816-22 pubmed publisher
    ..748 versus 0.680, P < 0.001) and 5 years (0.756 versus 0.699, P < 0.001). Collectively, our findings established the prognostic significance of ATG5 and FIP200 in patients with breast cancer. ..
  8. Yu K, Jiang Y, Hao S, Shao Z. Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer. BMC Med. 2015;13:254 pubmed publisher
    ..The majority of ER-/PgR+/HER2- phenotype breast cancers are basal-like and associated with a lower endocrine therapy sensitivity score. Additional studies are needed to validate these findings. ..
  9. Xie G, Liu Y, Jiang Y, Shao Z. Epidemiology and survival outcomes of mucinous adenocarcinomas: A SEER population-based study. Sci Rep. 2018;8:6117 pubmed publisher
    ..We also revealed a series of prognostic factors of MACs, including tumor sites, tumor grade and tumor stage, which may improve the current understanding of the clinical and biological patterns of MACs. ..

More Information


  1. Chen L, Yang L, Yao L, Kuang X, Zuo W, Li S, et al. Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients. Nat Commun. 2018;9:1357 pubmed publisher
    ..Collectively, these findings advance our understanding of PI3K impactful mutations in breast cancer and have important implications for PI3K-targeted therapy in precision oncology. ..
  2. Yin L, Shuang H, Sheng C, Liang H, Sun X, Yang W, et al. The Prognostic Value of Nodal Staging in Triple-Negative Breast Cancer - A Cohort from China. Sci Rep. 2018;8:9007 pubmed publisher
    ..We also found that tumor size made an impact on survival when lymph nodes were extensively involved, a finding that needs longer follow-up and further validation. ..
  3. Li J, Shao Z. Endocrine therapy as adjuvant or neoadjuvant therapy for breast cancer: selecting the best agents, the timing and duration of treatment. Chin Clin Oncol. 2016;5:40 pubmed publisher
  4. Tang L, Jin X, Yang H, He M, Chang H, Shao Z, et al. Luminal B subtype: a key factor for the worse prognosis of young breast cancer patients in China. BMC Cancer. 2015;15:201 pubmed publisher
    ..Luminal B subtype may have a negative effect on the prognosis of young patients in China which should be validated further. ..
  5. Liu Y, Jiang Y, Xu X, Yu K, Jin X, Hu X, et al. Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer. Breast Cancer Res. 2016;18:33 pubmed publisher
    ..If further validated in a larger population, our novel classification system could facilitate patient counseling and individualize treatment of TNBC. ..
  6. Kuang X, Jiang H, Li K, Zheng Y, Liu Y, Qiao F, et al. The phosphorylation-specific association of STMN1 with GRP78 promotes breast cancer metastasis. Cancer Lett. 2016;377:87-96 pubmed publisher
    ..We also propose a prognostic model based on phospho-STMN1 and GRP78 to assess metastatic risk in breast cancer patients. ..
  7. Li J, Jiang Y, Liu Y, Shao Z. Identify high risk estrogen receptor-positive breast cancer patients for extended endocrine therapy. Breast. 2017;31:173-180 pubmed publisher
  8. Wang D, Liu C, Wang J, Jia Y, Hu X, Jiang H, et al. Protein C receptor stimulates multiple signaling pathways in breast cancer cells. J Biol Chem. 2018;293:1413-1424 pubmed publisher
    ..To the best our knowledge, this is the first comprehensive study of PROCR signaling in breast cancer cells, and its findings also shed light on the molecular mechanisms of PROCR in stem cells in normal tissue. ..
  9. Yu S, Yang L, Hong Q, Kuang X, Di G, Shao Z. MicroRNA-200a confers chemoresistance by antagonizing TP53INP1 and YAP1 in human breast cancer. BMC Cancer. 2018;18:74 pubmed publisher
    ..Upregulated miR-200a enhances treatment resistance via antagonizing TP53INP1 and YAP1 in breast cancer. ..
  10. request reprint
    Mo M, Zheng Y, Liu G, Fang H, Zhang X, Zhai L, et al. [Cost-effectiveness analysis of two breast cancer screening modalities in Shanghai, China]. Zhonghua Zhong Liu Za Zhi. 2015;37:944-51 pubmed
    ..The organized screening costs more than opportunistic screening, but with a better cost-effectiveness. It may be used as an option in economically developed areas of China. ..
  11. Zheng J, Huang Y, Yao L, Liu Y, Liu S, Hu X, et al. Elevated miR-301a expression indicates a poor prognosis for breast cancer patients. Sci Rep. 2018;8:2225 pubmed publisher
    ..According to our results, miR-301a should be considered, and novel therapeutic options are needed to target this aggressive miR-301a-positive type of breast cancer to reduce recurrence and the mortality rate. ..
  12. Xu W, Liu Z, Hou Y, Hong Q, Hu D, Shao Z. Inhibition of autophagy enhances the cytotoxic effect of PA-MSHA in breast cancer. BMC Cancer. 2014;14:273 pubmed publisher
    ..MDA-MB-231HM cells. These findings demonstrated inhibiting autophagy together with PA-MSHA might be a promising therapeutic strategy in treating hormone receptor negative breast cancer cells. ..
  13. Chi Y, Huang S, Peng H, Liu M, Zhao J, Shao Z, et al. Critical role of CDK11(p58) in human breast cancer growth and angiogenesis. BMC Cancer. 2015;15:701 pubmed publisher
    ..The data suggested angiogenesis inhibition was dependent on CDK11(p58) kinase activity. This study indicates that CDK11(p58) inhibits the growth and angiogenesis of breast cancer dependent on its kinase activity. ..
  14. Xu H, Lin F, Wang Z, Yang L, Meng J, Ou Z, et al. CXCR2 promotes breast cancer metastasis and chemoresistance via suppression of AKT1 and activation of COX2. Cancer Lett. 2018;412:69-80 pubmed publisher
    ..Thus, antagonists of the CXCR2 signaling molecules may be used to treat breast cancer patients particularly with high metastasis and chemoresistance. ..
  15. Xiao Y, Ma D, Ruan M, Zhao S, Liu X, Jiang Y, et al. Mixed invasive ductal and lobular carcinoma has distinct clinical features and predicts worse prognosis when stratified by estrogen receptor status. Sci Rep. 2017;7:10380 pubmed publisher
    ..In both ER-positive and ER-negative subgroups, IDC-L predicts worse prognosis than IDC, which suggested the inadequacy of IDC-based therapy and the need of escalated therapy. ..
  16. Xie H, Shao Z, Li D. Tumor microenvironment: driving forces and potential therapeutic targets for breast cancer metastasis. Chin J Cancer. 2017;36:36 pubmed publisher
  17. Ma D, Jiang Y, Liu X, Liu Y, Shao Z. Clinical and molecular relevance of mutant-allele tumor heterogeneity in breast cancer. Breast Cancer Res Treat. 2017;162:39-48 pubmed publisher
    ..These results also suggest the origin and natural history of clonal evolution and intra-tumor genetic heterogeneity, which warrant further investigation. ..
  18. Wang R, Chen S, Jin X, Chen C, Shao Z. Weekly paclitaxel plus carboplatin with or without trastuzumab as neoadjuvant chemotherapy for HER2-positive breast cancer: loss of HER2 amplification and its impact on response and prognosis. Breast Cancer Res Treat. 2017;161:259-267 pubmed publisher
    ..Far more importantly, the loss of HER2 amplification could identify non-pCR patients with high risk of disease relapse, which might help in tailoring following systemic treatment. ..
  19. request reprint
    Alimujiang A, Mo M, Liu Y, Huang N, Liu G, Xu W, et al. The association between China's Great famine and risk of breast cancer according to hormone receptor status: a hospital-based study. Breast Cancer Res Treat. 2016;160:361-369 pubmed
    ..This retrospective analysis suggests that famine, malnutrition, or the associated lack of fruit and vegetable consumption in adulthood may be related to epidemiological heterogeneity within breast cancer subtypes. ..